Chronic Obstructive Pulmonary Disease (COPD)

← BACK  

Study 892 - This is a 3 to 4 year treatment study for patients with moderate COPD and a history of, or increased risk for, cardiovascular disease. Study visits occur every three months and take about 1 hour.

Study 898 - The purpose of this study is to investigate how well the study drug reduces the number of exacerbations (worsening of symptoms) in people with severe COPD, when used with a combination of two medications at an unchanged dose, known as a long-acting β2 agonist (LABA) and an inhaled corticosteroid (ICS). Some people in this study will get placebo (inactive substance) along with the LABA/ICS combinations to compare the effects of study drug with the LABA/ICS combinations. Participation will be approximately 58 weeks with up to 8 study visits. Follow up phone contacts will also be made during the study and approximately 30 days after study completion.

Study 928- This is a phase 4, multi-center, randomized, double-blind, placebo controlled, parallel group study evaluating the safety and efficacy of tiotropium bromide in patients recently hospitalized for a COPD exacerbation.

Study 930- The study is for COPD patients with moderate to severe airflow limitation.

Study 931- The study for COPD patients with moderate to severe airflow limitation.

For more information, please contact:

Mike Lay Clinical Research Coordinator
903-877-5465
903-877-5513 (fax)
email: michael.lay@uthct.edu